Clinical Trial Update: A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI) [Phase 1]

View source ↗

Summary

A Phase 1 study in asthma evaluated dose proportionality and absolute bioavailability of Fluticasone furoate inhalation powder delivered by a novel dry powder i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Arnuity Ellipta (Fluticasone furoate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 1 | Status: COMPLETED